Facebook
Twitter
LinkedIn
Forward
Clinical Brief: The Burden of Resistant Hypertension in Women - Novel and Emerging Approaches to Improve Outcomes
This clinical brief was developed from a presentation at the 2023 Women's Health and Wellness Masterclass held August 2023 in Dana Point, CA. The session, “Resistant Hypertension in Women: Dispelling Common Myths and Recent Clinical Advances,” was presented by Keith C. Ferdinand, MD, supported by an educational grant from Medtronic.
Target Audience
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.
Learning Objectives
After completing this activity, the participant should be better able to:
- Define resistant hypertension and its burden in women
- Explain evidence-based approaches for the screening and diagnosis of resistant hypertension in women
- Recognize the limitations of antihypertensive pharmacotherapy for resistant hypertension
- Summarize recent results with renal denervation and emerging pharmacotherapies for resistant hypertension as highlighted in pivotal clinical trials and real-world registries
- Identify comprehensive and individualized treatment options for women with resistant hypertension to optimize BP control and reduce the risk of adverse outcomes
Additional Information
| Attachment | Size |
|---|---|
 Clinical Brief PDF Download | 806.99 KB |
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine
Tulane University School of Medicine
New Orleans, LA
Dr. Ferdinand discloses the following:
- Consultant, Advisor, Speaker: Amgen, Novartis, Eli Lilly, Medtronic, Boehringer Ingelheim, Janssen
ESTIMATED TIME TO COMPLETE ACTIVITY
0.75 hour
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Medtronic, Inc.
JOINT PROVIDERSHIP STATEMENT
This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-317-H01-P. Type of activity: Knowledge
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period December 6, 2023 through December 6, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
DISCLOSURES
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.